1. On top of the dilution, they are now paying salespeople to sit around.
2. By not partnering with a major brand salespeople will only have one product to trot in to show doctors.
3. If there is a major issue with the distributor in India the FDA could shut this down until CEMP gets a distribution partner that meets FDA standards. If the active ingredient is not exactly the same all the previous trials, no matter how good they are and no matter the need for this anti biotic, could be shelved and new trials may be needed.
The risk here was very much in the open. I was vocal against all the dilution. The banks had a terrible year with underwritings and they sold CEMP lock stock and barrel on this dilution. It does not matter if the FDA loves the drug if there are issues with the active ingredient at the source.
Have made good trades here 3 times so CEMP doesn't owe us anything, but if they were offered in the 40's earlier in the year by a major partner they should have taken it.
Hope they figure this out quickly. It is bizarre that articles are being written about these issues without a press release. This is a material event if true
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM